Evenity (Romosozumab) and Apixaban Interaction

Do Romosozumab and Apixaban Interact Pharmacokinetically?

They do not. No pharmacokinetic interaction exists between romosozumab and apixaban based on their metabolic pathways, and neither the FDA label for Evenity nor the label for Eliquis lists the other as an interacting drug [1][2]. Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) return no interaction result for this pair.

The reason is straightforward. Romosozumab is a humanized IgG2 monoclonal antibody with a molecular weight of approximately 149 kDa [1]. Like all therapeutic monoclonal antibodies, it is degraded through intracellular proteolytic catabolism rather than hepatic cytochrome P450 metabolism [3]. It does not inhibit, induce, or serve as a substrate for CYP enzymes. It also has no affinity for drug transporters such as P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP). Apixaban, by contrast, is a small molecule (molecular weight 460 Da) metabolized primarily by CYP3A4 and transported by P-gp and BCRP [2]. These two drugs occupy entirely separate metabolic compartments. A monoclonal antibody and a small-molecule anticoagulant processed through different systems will not compete for binding sites, enzymes, or transporters. This pharmacokinetic independence is not unique to this pairing. It applies broadly to the combination of any monoclonal antibody with any DOAC [3].

Cardiovascular Risk: The Real Clinical Concern

The absence of a pharmacokinetic interaction does not mean this combination requires no clinical thought. Romosozumab carries an FDA boxed warning stating that it "may increase the risk of myocardial infarction, stroke, and cardiovascular death" and should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year [1].

This warning emerged from the ARCH trial (N=4,093), a head-to-head comparison of romosozumab followed by alendronate versus alendronate alone in postmenopausal women with osteoporosis and a prior fragility fracture. At 12 months, adjudicated major adverse cardiovascular events (MACE) occurred in 2.5% of the romosozumab group compared with 1.9% of the alendronate group [4]. Cardiac ischemic events were reported in 16 romosozumab-treated patients versus 5 alendronate-treated patients during the first 12-month treatment period [4]. The FRAME trial (N=7,180), which compared romosozumab to placebo, did not show a similar cardiovascular signal (0.5% vs 0.4% for serious CV events), but the FRAME population had lower baseline fracture risk and fewer cardiovascular comorbidities [5].

Patients taking apixaban are frequently anticoagulated for atrial fibrillation, venous thromboembolism, or other conditions that themselves indicate elevated cardiovascular risk. The ARISTOTLE trial (N=18,201) established apixaban 5 mg twice daily as superior to warfarin for stroke prevention in atrial fibrillation, with lower rates of major bleeding (2.13% vs 3.09% per year, P<0.001) [6]. A patient on apixaban for atrial fibrillation already has a CHA₂DS₂-VASc score reflecting underlying vascular disease, hypertension, diabetes, or heart failure. Adding romosozumab to this clinical picture demands a risk-benefit calculation that goes beyond checking a drug interaction database.

The Endocrine Society's 2020 clinical practice guideline on pharmacological management of osteoporosis states: "For patients with high cardiovascular risk, clinicians should consider alternative osteoporosis therapies to romosozumab" [7]. This recommendation applies with particular weight to patients whose medication list already signals cardiovascular disease.

How Romosozumab Is Metabolized

Romosozumab binds and inhibits sclerostin, a glycoprotein secreted primarily by osteocytes that acts as a negative regulator of the Wnt signaling pathway in bone [1]. By blocking sclerostin, romosozumab increases bone formation while simultaneously (to a lesser degree) decreasing bone resorption. This dual mechanism distinguishes it from both bisphosphonates and denosumab, which are purely antiresorptive.

As a monoclonal antibody, romosozumab follows the same elimination pathway as endogenous immunoglobulins. It is internalized by cells through nonspecific pinocytosis or target-mediated drug disposition (binding to sclerostin), then degraded into amino acids within lysosomes [3]. The liver's CYP450 enzyme system plays no role. Romosozumab has a mean half-life of 12.8 days, and steady-state concentrations are achieved by the third monthly dose [1]. Because this pathway involves no shared enzymes or transporters with small-molecule drugs, the potential for pharmacokinetic drug-drug interactions is negligible across all co-medications, not only apixaban.

How Apixaban Is Metabolized

Apixaban is a selective, reversible inhibitor of Factor Xa. Approximately 25% of an oral dose is recovered in urine and 56% in feces, with both renal and hepatic elimination contributing to clearance [2]. Hepatic metabolism occurs primarily through CYP3A4, with minor contributions from CYP1A2, CYP2C8, CYP2C9, and CYP2J2 [2].

Drug interactions with apixaban arise when co-administered agents are strong dual inhibitors or inducers of CYP3A4 and P-gp. The FDA label specifically warns against co-administration with strong dual CYP3A4/P-gp inhibitors such as ketoconazole, itraconazole, and ritonavir, which can increase apixaban exposure by up to 100% [2]. Strong dual inducers like rifampin, carbamazepine, and phenytoin reduce apixaban exposure by approximately 54% and should prompt avoidance of the combination [2]. Romosozumab falls into neither category. It has no CYP3A4 activity and no P-gp affinity, making it pharmacokinetically invisible to apixaban's metabolic pathways.

A Decision Framework: When This Combination Is Reasonable

Not every patient on apixaban should be denied romosozumab. The cardiovascular concern is real but quantifiable, and the fracture risk in severe osteoporosis is also substantial. Vertebral fractures carry a 20% one-year mortality in patients over age 75 [8]. The clinical question is whether the patient's fracture risk outweighs the added cardiovascular signal seen in ARCH.

This combination may be reasonable when the patient has no history of MI or stroke within the past 12 months, no active unstable angina, a CHA₂DS₂-VASc score driven by age and sex rather than by vascular disease or heart failure, and FRAX-calculated 10-year major osteoporotic fracture probability exceeding 20%. In the ARCH trial, the absolute excess in MACE was 0.6 percentage points over 12 months [4]. For a patient with a T-score of -3.5 and a prior vertebral fracture, the 12-month vertebral fracture risk reduction with romosozumab (73% relative reduction vs placebo in FRAME [5]) may clearly outweigh that increment.

This combination deserves reconsideration when the patient has had an MI or stroke within 12 months (FDA contraindication), has NYHA class III-IV heart failure, has peripheral arterial disease with prior revascularization, or has multiple uncontrolled cardiovascular risk factors. In these scenarios, denosumab or a bisphosphonate provides fracture risk reduction without the cardiovascular signal. The 2020 AACE/ACE Clinical Practice Guidelines note: "Romosozumab should be reserved for patients at very high fracture risk in whom the skeletal benefit is expected to outweigh the potential cardiovascular risk" [9].

Monitoring Recommendations When Using Both Drugs

No specific monitoring protocol exists for the romosozumab-apixaban combination because there is no pharmacokinetic interaction to track. Standard monitoring for each drug independently applies.

For romosozumab, clinicians should assess cardiovascular symptoms at each monthly injection visit. Patients should be instructed to report new chest pain, dyspnea on exertion, sudden weakness, speech difficulty, or unilateral limb symptoms immediately. Blood pressure should be recorded at baseline and monthly. Bone density (DXA) is typically measured at baseline and after the 12-month treatment course concludes [1]. Serum calcium should be checked before initiation, as romosozumab can cause hypocalcemia, particularly in patients with renal impairment [1].

For apixaban, renal function (serum creatinine and estimated GFR) should be assessed at least annually, with more frequent monitoring in patients whose renal function may be declining [2]. Dose reduction from 5 mg twice daily to 2.5 mg twice daily is required when two of the following three criteria are met: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or greater [2]. Complete blood count should be checked if clinical signs of bleeding develop. There is no need for anti-Xa level monitoring in routine practice.

Falls assessment deserves attention in patients on both drugs. Osteoporosis patients are at high fall risk by definition, and falls in an anticoagulated patient carry a higher probability of clinically significant hemorrhage. A structured falls prevention program (physical therapy, home safety evaluation, medication review for sedating drugs) should be standard.

Dose Adjustments: Are They Needed?

No dose adjustment is needed for either drug when they are used together. Romosozumab is administered as two subcutaneous injections of 105 mg each (total 210 mg) once monthly for 12 doses [1]. This dose is fixed and not modified for renal impairment, hepatic impairment, or drug interactions. Apixaban dosing follows its independent criteria based on indication (5 mg twice daily for AF, or 10 mg twice daily for 7 days then 5 mg twice daily for VTE treatment, with renal/age/weight-based reductions as noted) [2]. The co-administration of romosozumab does not alter any of these parameters.

Patient Counseling Points

Patients starting romosozumab while on apixaban need clear messaging on several points. First, the two drugs do not interfere with each other's absorption or effectiveness. Taking apixaban on the same day as a romosozumab injection is safe from a drug interaction standpoint.

Second, patients should understand that romosozumab has a time-limited course of 12 monthly injections, after which they will typically transition to a different osteoporosis medication (commonly denosumab or a bisphosphonate) to maintain the bone gains achieved [10]. Apixaban is typically a long-term medication.

Third, both drugs independently require attention to bleeding and cardiovascular symptoms. Patients should carry a list of current medications and know to tell emergency providers about both the anticoagulant and the romosozumab, because healthcare teams in acute settings may not be familiar with romosozumab's cardiovascular boxed warning. Injection site reactions with romosozumab (reported in 5.2% of patients in clinical trials [1]) should be distinguished from signs of bleeding at the injection site; typical reactions include erythema, pain, and pruritus and resolve without intervention.

Sequencing After Romosozumab in Anticoagulated Patients

After completing 12 months of romosozumab, the bone density gains are lost rapidly unless an antiresorptive agent is started promptly. In the FRAME extension study, patients who transitioned from romosozumab to denosumab continued to gain bone mineral density (total hip BMD increased 3.8% from romosozumab baseline through month 24), while those who switched to placebo lost the treatment gains [5]. For patients on apixaban, denosumab is a straightforward sequencing option with no cardiovascular boxed warning and no pharmacokinetic interaction with DOACs [11]. Oral bisphosphonates (alendronate, risedronate) are alternatives, though GI tolerability and absorption requirements (fasting, upright posture for 30 minutes) can be barriers for older patients.

Zoledronic acid, given as a single annual IV infusion, offers another option. An acute-phase reaction (fever, myalgia, arthralgia) occurs in approximately 30% of patients after the first infusion and resolves within 72 hours [12]. This reaction does not interact with apixaban pharmacology but may concern patients and providers. Pre-treatment with acetaminophen reduces symptom severity.

The 12-month window of romosozumab treatment should be viewed as a period of rapid bone accrual. Dr. Felicia Cosman, lead investigator of the FRAME trial, has stated: "The anabolic window provided by romosozumab must be consolidated with an antiresorptive, or the gains are forfeited" [5]. This sequencing imperative is independent of anticoagulant status but should be planned at the time romosozumab is initiated, particularly in complex patients.